Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumor Grade 3 × NET × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 454 Gastro-enteropancreatic neuroendocrine tumor 49 Carcinoid Tumor 49 Neoplasms 41 Carcinoma, Neuroendocrine 35 Adenoma, Islet Cell 29 Pancreatic Neoplasms 26 Neoplasm Metastasis 23 Pheochromocytoma 22 Paraganglioma 21 Colorectal Neoplasms 20 Stomach Neoplasms 18 Carcinoma, Hepatocellular 18 Carcinoma 17 Prostatic Neoplasms 16 Gastrointestinal Neoplasms 16 Sarcoma 15 Thyroid Neoplasms 14 Lung Neoplasms 14 Breast Neoplasms 14 Neuroblastoma 13 Serotonin Syndrome 12 Small Cell Lung Carcinoma 10 Esophageal Neoplasms 10 Adenocarcinoma 10 Melanoma 9 Digestive System Neoplasms 9 Colonic Neoplasms 9 Cholangiocarcinoma 9 Carcinoma, Renal Cell 9

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡